Nearly all participants (11 of 12) experienced clinically meaningful hearing improvements, including three who achieved normal hearing; eight with longer…
mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire /…
NASHVILLE, Tenn., Oct. 10, 2025 /PRNewswire/ -- Thyme Care and American Oncology Network (AON) announced today that nine jointly developed research abstracts…
MESA, ARIZONA / ACCESS Newswire / October 10, 2025 / Medical Care Technologies Inc. (OTC Pink:MDCE), an emerging leader in…
Taipei, Taiwan, Oct. 10, 2025 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology…
CHICAGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global…
Presentation title: “Advancing Alzheimer’s Disease Care: Convenience for Both Patients and Families with Oral Blarcamesine” NEW YORK, Oct. 10, 2025…
iBrain™ - Copyright © 2025 NeuroVigil, Inc. All Rights Reserved. iBrain™ prototype iBrain™ with two quarters - Copyright © 2025…
GAITHERSBURG, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a…
Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical…